Medicamen Biotech (BOM:531146) Tariff Resilience Score: 0/10 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531146 Medicamen Biotech Ltd BOM:531146
62 GF Score
Price ₹240.75
GF Value ₹512.38
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicamen Biotech Tariff Resilience Score?

Medicamen Biotech has the Tariff Resilience Score of 0, which implies that the company might have .

Medicamen Biotech has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Medicamen Biotech might have .

Medicamen Biotech  (BOM:531146) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Medicamen Biotech Tariff Resilience Score Related Terms

BOM:531146
62GF Score
Medicamen Biotech Ltd BOM:531146
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medicamen Biotech (BOM:531146) Overvalued in 2026?

Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued. The current stock price of ₹240.75 is trading 53% below its estimated GF Value™ of ₹512.38. GuruFocus considers Medicamen Biotech to be Possible Value Trap.

Key valuation signals for BOM:531146:

  • Tariff Resilience Score: 0
  • GF Value™: ₹512.38 vs. price of ₹240.75 (53% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the BOM:531146 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicamen Biotech Business Description

Other Exchanges MEDICAMEQ:India
Address 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
62GF Score

Get the complete analysis for BOM:531146

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹240.75
Price
₹512.38
GF Value